Is Capmatinib a targeted drug?

Capmatinib (Capmatinib) is a targeted drug. Targeted drugs are a class of drugs that interfere with the growth and spread of cancer cells through specific targets. These targets are usually key proteins, receptors or kinases in cancer cells, which play an important role in the development of cancer. By targeting these targets, targeted drugs can more precisely interfere with the abnormal signaling of cancer cells, thereby inhibiting the growth and spread of tumors while minimizing damage to normal cells.

Capmatinib targets METkinase, which is specifically targeted at patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. METExon 14 skipping mutations lead to abnormal activation of MET kinase, thereby promoting the growth and spread of cancer cells. Capmatinib inhibits the activity of MET kinase and interferes with abnormal signaling, thereby slowing or inhibiting tumor development.

The advantage of targeted drugs is that they are generally more selective and therefore can target cancer cells more effectively, causing less damage to normal cells, while potentially causing fewer side effects. However, each targeted drug has specific mechanisms of action and indications, so patients should make individualized treatment choices based on their doctor's recommendations.

Capmatinib is not currently on the market in China, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug from Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about 3,000 to 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.

xa0